Literature DB >> 21214332

Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.

Natsuki Shinozaki1, Yoshio Uchino, Kyosan Yoshikawa, Tomoo Matsutani, Azusa Hasegawa, Naokatsu Saeki, Yasuo Iwadate.   

Abstract

OBJECT: The diagnostic usefulness of (11)C-methionine PET scans in gliomas is still controversial. The authors investigated the clinical significance of (11)C-methionine PET findings in preoperative diagnosis of histological type and grade.
METHODS: The tissue uptake of (11)C-methionine was assessed using PET in 70 patients with histologically confirmed intracerebral gliomas. The ratio of maximum standard uptake values in tumor areas to the mean standard uptake values in the contralateral normal brain tissue (tumor/normal tissue [T/N] ratio) was calculated and correlated with tumor type, histological grade, contrast enhancement on MR imaging, Ki 67 labeling index, and 1p/19q status.
RESULTS: The T/N ratio was significantly increased as tumor grade advanced in astrocytic tumors (WHO Grade II vs Grade III, p = 0.0011; Grade III vs Grade IV, p = 0.0007). Among Grade II gliomas, the mean T/N ratio was significantly higher in oligodendroglial tumors than in diffuse astrocytomas (DAs) (p < 0.0001). All T/N ratios for oligodendroglial tumors were ≥ 1.46, and those for DA were consistently < 1.46, with the exception of 2 cases of gemistocytic astrocytoma. The Ki 67 labeling index significantly correlated with T/N ratio in astrocytic tumors, but not in oligodendrogliomas. Oligodendroglial tumors without 1p/19q deletion had a significantly higher T/N ratio than those with the codeletion. In combination with Gd-enhanced MR imaging, 67% of nonenhanced tumors with a T/N ratio of ≥ 1.46 were proved to be Grade II oligodendrogliomas.
CONCLUSIONS: These results clearly show that (11)C-methionine PET T/N ratios in Grade II oligodendrogliomas were higher than those in DAs independently of their proliferative activity. This information contributes to preoperative differential diagnoses of histological type, especially in suspected low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21214332     DOI: 10.3171/2010.11.JNS10553

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

2.  "The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?

Authors:  Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

Review 3.  11C-methionine PET/CT findings in benign brain disease.

Authors:  Reiko Nakajima; Ken Kimura; Koichiro Abe; Shuji Sakai
Journal:  Jpn J Radiol       Date:  2017-04-18       Impact factor: 2.374

4.  Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.

Authors:  Anna Latysheva; Kyrre Eeg Emblem; Petter Brandal; Einar Osland Vik-Mo; Jens Pahnke; Kjetil Røysland; John K Hald; Andrés Server
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

Review 5.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

6.  Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Authors:  K Tateishi; U Tateishi; M Sato; S Yamanaka; H Kanno; H Murata; T Inoue; N Kawahara
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

Review 7.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

8.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

9.  Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.

Authors:  Yuji Nakamoto; Kensuke Kurihara; Masatoshi Nishizawa; Kouhei Yamashita; Koya Nakatani; Tadakazu Kondo; Akifumi Takaori-Kondo; Kaori Togashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

10.  Stereotactic image-based histological analysis reveals a correlation between 11C-methionine uptake and MGMT promoter methylation in non-enhancing gliomas.

Authors:  Yoshiko Okita; Tomoko Shofuda; Daisuke Kanematsu; Ema Yoshioka; Yoshinori Kodama; Masayuki Mano; Manabu Kinoshita; Masahiro Nonaka; Shin Nakajima; Toshiyuki Fujinaka; Yonehiro Kanemura
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.